This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Shanghai Microport Cardioflow Medtech Co., Ltd.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: **Yemeng Chen: Pioneering Innovations in Bioprocessing**
Introduction
Yemeng Chen is an accomplished inventor based in Shanghai, China, known for his significant contributions to the field of bioprocessing. With one patented innovation, he has developed a method for creating dry animal-derived collagen fiber tissue materials, which has the potential to revolutionize bioprothesis applications.
Latest Patents
Yemeng Chen's notable patent is titled "Dry animal-derived collagen fiber tissue material and preparation method and bioprothesis thereof." This innovation encompasses a cutting-edge preparation method that enhances the properties of collagen fibers while ensuring affordability and efficiency. The steps include rinsing the collagen material, dehydration using a non-aqueous alcoholic solution, gradient dehydration with saccharide solutions, and ultimately hermetically packaging the dried material. This method not only minimizes costs by using readily available materials but also reduces toxicity from residual crosslinking agents, resulting in a biocompatible and pliable product.
Career Highlights
Currently, Chen is associated with Shanghai Microport Cardioflow Medtech Co., Ltd., where he continues to focus on advancements in medical materials. His work emphasizes using innovative techniques to enhance the usability and safety of bioprothesis, contributing to better patient care outcomes.
Collaborations
In his professional journey, Yemeng Chen collaborates with notable colleagues such as Jiaoming Dong and Guanbiao Xu. These partnerships highlight the collective effort in pushing the boundaries of research and development within the bioengineering field.
Conclusion
Yemeng Chen’s work and innovations in the realm of collagen fiber tissue materials represent a significant step forward in both research and practical applications. His patented preparation method not only improves the accessibility of bioprothesis technology but also enhances the quality of life for patients requiring such solutions. As he continues his endeavors at Shanghai Microport Cardioflow Medtech Co., Ltd., the potential impact of his work will undoubtedly resonate within the medical community and beyond.